BeyondSpring to present predictive biomarker data for Plinabulin at AACR
BeyondSpring announced that the company will present data relevant to predictive biomarkers for patient selection for its lead asset, Plinabulin, at the American Association for Cancer Research, or AACR. The results from this non-clinical study will be highlighted in a poster presentation. In this study, BeyondSpring generated neural and logistic regression algorithms that utilized Affymetrix array-based mRNA measurements to predict the ability of Plinabulin to reduce the number of live breast, lung, prostate, ovarian and CNS cancer cells in vitro. Predictive genes include CTNNB1, CALD1, ERI1, LGR5, SECISBP2L and TRAK1. The methods and predictive gene mRNAs discovered will be utilized to introduce a similar exploratory approach into Plinabulin clinical trials.